

Ibrance - (75, 100, 125 mg; Capsule, Oral)

| Generic Name | Palbociclib | Innovator | Pfizer |
|-----------------------|---|----------------------|---------------------|
| Dosage | 75, 100, 125 mg; Capsule, Oral | Branded US Sales | More Than \$1000 mn |
| Probable FTF | More Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | More Than 5 |
| Final Approvals | None | Generic Launches | None |
| Indication | Indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Executive Summary

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Patent Status

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Launch Timelines and Competition

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Chronology Of Events

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.



Ibrance - (75, 100, 125 mg; Tablet)

| Generic Name | Palbociclib | Innovator | Pfizer |
|-----------------------|---|----------------------|---------------------|
| Dosage | 75, 100, 125 mg; Tablet | Branded US Sales | More Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | None | Generic Launches | None |
| Indication | IBRANCE is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or fulvestrant in women with disease progression following endocrine therapy. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Executive Summary

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Patent Status

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Launch Timelines and Competition

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Chronology Of Events

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.